Latest Recce Pharmaceuticals (ASX:RCE) News
Page 4
Page 4 of 5
Recce Advances Phase 3 Trial and Secures $85M R&D Funding Eligibility
30 Jan 2026
Recce Pharmaceuticals Secures $5.3m R&D Rebate to Boost Anti-Infective Trials
14 Jan 2026
Recce Pharmaceuticals Secures A$85M R&D Tax Incentive Boost for Global Antibiotic Fight
16 Dec 2025
Recce Pharmaceuticals Expands Asian Patent Reach with Hong Kong Approval
27 Nov 2025
Recce’s Inhaled RECCE 327 Slashes Drug-Resistant Pneumonia in Preclinical Tests
26 Nov 2025
Recce Pharmaceuticals Advances Phase 3 Trial Amid Strong Antibacterial Data
31 Oct 2025
Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infection Treatment in Indonesia
25 Sept 2025
Recce Pharmaceuticals Advances Phase 3 Trials Amid Rising Losses
29 Aug 2025
Recce’s RECCE 327 Gel Accelerates Healing in Drug-Resistant Burn Wounds
12 Aug 2025
Recce Pharmaceuticals Secures $15.8M Capital Raise Amid Phase 3 Trial Expansion
31 July 2025
Recce Pharmaceuticals Secures A$30M Debt Facility to Fuel Phase 3 Trials and Market Launch
17 June 2025
Recce Pharmaceuticals Secures A$15.8M to Advance Critical Phase 3 Trials
3 June 2025